Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:MBX NASDAQ:SBTX NASDAQ:ZFGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.90-2.2%$8.65$56.35▼$105.00$228.98M0.9512,438 shs47,960 shsMBXMBX Biosciences$15.09+5.7%$13.06$4.81▼$27.50$506.93MN/A324,882 shs154,165 shsSBTXSilverback Therapeutics$11.62-9.6%$16.62$2.80▼$8.97$418.99M0.6337,931 shs7.18 million shsZFGNZafgen$3.62-7.4%$18.47$0.62▼$2.76$135.64M0.27360,199 shs1.40 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-4.01%+9.87%+8.97%-88.30%MBXMBX Biosciences0.00%+5.30%+9.75%+14.84%+1,508,999,900.00%SBTXSilverback Therapeutics0.00%-13.93%-34.28%-19.47%-10.48%ZFGNZafgen0.00%-7.42%+4.62%+60.89%-54.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.1519 of 5 stars3.50.00.00.02.11.70.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63149.34% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/AZFGNZafgen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ZFGN, MBX, SBTX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/AZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78MBXMBX BiosciencesN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87ZFGNZafgen0.266.566.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AMBXMBX BiosciencesN/ASBTXSilverback Therapeutics74.89%ZFGNZafgen70.43%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%MBXMBX Biosciences52.19%SBTXSilverback Therapeutics34.40%ZFGNZafgen14.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/ASBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableZFGNZafgen3837.47 millionN/ANot OptionableZFGN, MBX, SBTX, and AVTE HeadlinesRecent News About These CompaniesGSK/Sirtris compounds dogged by assay artifactsMay 21, 2024 | nature.comNTokyo Steel Manufacturing Co Ltd 5423May 16, 2024 | morningstar.comMDiagnosing Diabetes: Not So SimpleNovember 2, 2023 | medscape.comMDo New Weight Loss Meds Mean the End of Bariatric Surgery?October 6, 2023 | medscape.comMPrader-Willi syndromeAugust 23, 2023 | pharmaphorum.comPThe Omnipod 5 System: Trial Results From ENDO 2021August 4, 2023 | medscape.comMBeta Cells From Stem Cells: Nearing a Cure for Type 1 Diabetes?July 5, 2023 | medscape.comMOral Semaglutide Brings GLP-1s to Primary CareMay 20, 2023 | medscape.comMClinical Trials - Different Phases of the trial News, Research and Latest UpdatesMay 20, 2023 | medindia.netMObesity Therapeutic Pipeline Analysis, 2023 Updates | Insights into ... - Digital JournalMay 12, 2023 | news.google.comNWeight Loss and Obesity Management Market Insights With ... - Taiwan NewsMay 11, 2023 | news.google.comNGlobal Methionine Aminopeptidase 2 Market Report 2023 by Trend ... - The Northwestern ExaminerMay 4, 2023 | news.google.comNWeight Loss and Obesity Management Market May See a Big Move ... - Digital JournalMay 2, 2023 | news.google.comNIronwood Pharmaceuticals: A Promising Outlook for Long-Term ... - Best StocksMay 2, 2023 | news.google.comNThe Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the CirculationApril 29, 2023 | medscape.comMFast Five Quiz: Type 2 Diabetes and Dyslipidemia - Medscape ReferenceApril 21, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Share, Economic Growth, Emerging ... - Digital JournalApril 20, 2023 | news.google.comNAnti-Obesity Drugs Market Size, Analysis, Share, Research, Business Growth and Forecast to 2031 - openPRApril 14, 2023 | news.google.comNNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMNew ADA Standards: Promoting HealthApril 13, 2023 | medscape.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZFGN, MBX, SBTX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.90 -0.18 (-2.23%) As of 08/29/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.MBX Biosciences NYSE:MBX$15.09 +0.82 (+5.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.04 -0.05 (-0.33%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Silverback Therapeutics NASDAQ:SBTX$11.62 -1.24 (-9.64%) As of 08/29/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Zafgen NASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
